Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Biopharma Credit Plc LSE:BPCR London Ordinary Share GB00BDGKMY29 ORD USD0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.008 -0.81% 0.98 0.98 0.984 0.988 0.98 0.99 1,493,348 16:14:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Unknown 142.3 113.8 8.3 11.8 1,346

Biopharma Credit Share Discussion Threads

Showing 26 to 49 of 50 messages
Chat Pages: 2  1
DateSubjectAuthorDiscuss
19/2/2021
16:47
GBP strength not helping?
jonwig
19/2/2021
16:04
Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/84386891 As at the 31 January 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 100.84 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com.
speedsgh
22/12/2020
11:34
True, but my broker (ii) lets me have a USD account, so I'm not too bothered. And gold is a useful hedge against weaker dollar.
jonwig
22/12/2020
11:28
Currency has been the issue
tiltonboy
22/12/2020
10:19
"...but not a particularly excited one." That's probably a good thing. When it comes to investments, boring suits me down to the ground.
speedsgh
22/12/2020
07:04
speeds - thanks for keeping us up to date with this! I'm still a contented holder, but not a particularly excited one.
jonwig
21/12/2020
21:16
Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/83953848 As at the 30 November 2020 the unaudited net asset value per Ordinary Share, including current period revenue, was 99.91 cents. The Company's factsheet and investor presentation will be located on the Company's website, hxxp://bpcruk.com.
speedsgh
07/12/2020
13:01
Latest Edison update (issued 24 Nov)... Reinvesting proceeds from loan prepayments - HTTPS://www.edisongroup.com/wp-content/uploads/2020/11/Biopharma-Credit-Reinvesting-proceeds-from-loan-prepayments.pdf
speedsgh
12/11/2020
11:42
Dividend Declaration - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/dividend-declaration/202011120700060560F/ BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the financial period ending 30 September 2020 of $0.0175 per ordinary share and a small special dividend in respect of the financial period ending 31 December 2019 of $0.0001 per ordinary share, payable on 18 December 2020 to ordinary shareholders on the register as at 20 November 2020. The Company has a small revenue reserve remaining for the fiscal year 2019 that it is distributing to ordinary shareholders. The Company has chosen to designate the entire amount of this interim and special dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company. The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.
speedsgh
09/11/2020
08:21
ADDITIONAL INVESTMENT IN EPIZYME - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/additional-investment-in-epizyme/202011090700115786E/ BioPharma Credit PLC (the "Company"), is pleased to announce that it, through its fully owned subsidiary, together with BioPharma Credit Investments V (Master) LP ("BioPharma-V" and jointly with the Company the "Lenders",) has entered into an amended and restated loan agreement with Epizyme, Inc ("Epizyme") dated 3 November 2020. As part of this amendment, the Company will invest an additional US$75 million in the Epizyme loan. Under the original terms of the loan agreement, executed in November 2019, Epizyme borrowed US$70 million in three tranches and the Company previously invested US$35 million with BioPharma-V investing the US$35 million balance. The original US$70 million loan will mature in November 2024 and bears interest at LIBOR plus 7.75 per cent. per annum along with a one-time additional consideration of 2.00 per cent. of the total loan amount. In addition, the facility was expandable by up to US$300 million, subject to mutual agreement between the Lenders and Epizyme after approval of tazemetostat for the treatment of follicular lymphoma. On 23 January 2020, TAZVERIK® was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with epithelioid sarcoma and on 18 June 2020 TAZVERIK received accelerated approval from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma. The amendment increases the aggregate principal amount of the loan to Epizyme to US$220 million through a US$150 million fourth tranche ("Tranche D"), which the parties expect to be drawn in full on 18 November 2020. The Company will invest US$75 million of the US$150 million Tranche D and BioPharma-V will invest the US$75 million balance. Tranche D will have the same fees and coupon as the earlier tranches, will be secured by the same collateral as the earlier tranches, and will mature in November 2026 after eight equal amortization payments beginning in February 2025. As part of the amendment, the amortization terms of the initial US$70 million advanced in the first three tranches were changed from eight equal quarterly payments starting in February 2023 to four equal quarterly payments starting in February 2024. Following the expected Tranche D closing, the facility will remain expandable by up to an additional US$150 million, subject to mutual agreement between the Lenders and Epizyme. "We are delighted to expand our partnership with Epizyme", said Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP. "TAZVERIK is now approved to meet the well-defined unmet patient needs in two very different indications (a solid tumor and a hematologic malignancy), demonstrating its broad therapeutic potential." Further to the 4 November 2019 announcement of the original loan agreement, Royalty Pharma continues to hold approximately 9.1% of the issued share capital of Epizyme and Pablo Legorreta, a principal of Pharmakon and Royalty Pharma, continues to be a member of Epizyme's board of directors.
speedsgh
21/10/2020
18:04
Thanks for posting Looks pleasingly boring
williamcooper104
21/10/2020
17:39
Net Asset Value(s) and Monthly Factsheet - HTTPS://data.fca.org.uk/artefacts/NSM/RNS/3755523.html As at the 30 September 2020 the unaudited net asset value per Ordinary Share, including current period revenue, was 101.00 cents. The Company's factsheet will be located on the Company's website, HTTP://bpcruk.com.
speedsgh
02/10/2020
14:37
Director buys... On 30/9 Rolf Soderstrom (Director) bought 50,000 shares at £0.787344 = £39,367 HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/director-pdmr-shareholding/202010011100018035A/ On 30/9 Linda Davey (PCA to Rolf Soderstrom, Director of BioPharma Credit PLC) bought 50,000 shares at £0.787344 = £39,367 HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/director-pdmr-shareholding/202010011100018034A/
speedsgh
28/9/2020
15:06
STATEMENT REGARDING SAREPTA THERAPEUTICS - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/statement-regarding-sarepta-therapeutics/202009280700052023A/ BioPharma Credit PLC (the "Company"), is pleased to announce that, together with Sarepta Therapeutics, Inc ("Sarepta"), and BioPharma Credit Investments V (Master) LP ("BioPharma-V") it has entered into a first amendment to the loan agreement dated 13 December 2019. Under the original terms of the loan agreement, the Company agreed to invest up to US$350 million (US$175 million in the first tranche ("Tranche A") and up to an additional US$175 million by 31 December 2020 ("Tranche B")) and BioPharma-V agreed to invest up to US$150 million in parallel with the Company acting as collateral agent. The loan had an original maturity date of December 2023 and paid interest at 8.50 per cent. per annum along with a one-time additional consideration of 1.75 per cent. of the total loan amount payable upon funding and an additional 2.00 per cent. payable upon the repayment of the loan. The amendment increases the aggregate principal amount of Tranche B from US$250 million to US$300 million. The Company's investment in Tranche B will remain unchanged at US$175 million while BioPharma-V will increase its investment by US$50 million. The Company's US$350 million aggregate investment in Sarepta will represent 25% of the Company's portfolio. Sarepta has agreed to draw Tranche B in full, on or prior to 2 November 2020, as long as the conditions to funding the Tranche B are satisfied or waived. In addition, the Amendment extends the maturity date for the Tranche B Loan to 31 December 2024 and increases the funding fee payable to each Lender providing a portion of the Tranche B Loan on the date the Tranche B Loan is funded by 1.20 per cent. to 2.95 per cent.
speedsgh
16/9/2020
13:22
Half-year Report - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/half-year-report/202009160700050954Z/ Pedro Gonzalez de Cosio, CEO and co-founder of Pharmakon Advisors L. P., the Investment Manager of BioPharma Credit PLC, said: "During the first six months of 2020, Covid-19 has brought exceptional challenges to the global economy resulting in volatile conditions for many sectors and a significant reduction in global dividends. However, as a result of the Company's uncorrelated revenue stream, dividend payments have continued uninterrupted towards the ongoing annual target of 7 cents per share, just above a 7% dividend yield to our investors on the 30 June share price. It is the Company's objective to continue to offer a highly attractive long-term source of income uncorrelated to other markets. "The Company's investment activity in deploying specialised debt investments such as senior secured loans backed by important life science products has continued as normal with one significant new investment in Collegium Pharmaceuticals during the period and additional follow-on commitments in addition to some attractive pre-payments post-period end. "The environment continues to be attractive for the Company's investment strategy given the considerable and growing capital needs of the sector. This will be potentially enhanced by an anticipated increase in sector M&A activity and a slowdown in equity issuance that has tended historically to lead to a greater appetite for fixed income as a source of capital for the life sciences industry."
speedsgh
29/5/2020
03:02
More good news. The hefty Invesco overhang is gone: https://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Holdings-in-Company/82554964 I found this relevantly interesting: hTtps://capitalallocatorspodcast.com/2020/05/31/healthcare-royalty-partners/
rambutan2
26/5/2020
20:11
As predicted, and a good thing imho: NEW CREDIT FACILITY BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to announce that it has entered into a US$200 million credit facility (the "Credit Facility") with JPMorgan Chase Bank. The Credit Facility comprises a three-year US$200 million Revolving Credit Facility ("RCF"). The Company will pay a commitment fee on undrawn amounts of 200 basis points and a LIBOR margin of 400 basis points on drawn amounts. All borrowings under the Credit Facility are subject to compliance with certain covenants and the Company has provided charges over its subsidiaries' assets, including a charge over its subsidiaries' cash account and a floating charge over all of its subsidiaries' assets. As disclosed in the Company's latest Investor Update, as at 31 March 2020 the Company had a net cash position of US$64.3 million, or 5 per cent. of the Company's net asset value. Should the Revolving Credit Facility be fully drawn, aggregate borrowings would represent approximately 13 per cent. of the Company's net asset value. According to its Articles of Association, the Company may incur indebtedness of up to a maximum of 50 per cent. of its net asset value, calculated at the time of drawdown, for investment and for working capital purposes. Pharmakon Advisors, LP, the Company's Investment Manager, has agreed not to incur aggregate borrowings greater than 25 per cent. of the Company's net asset value, calculated at the time of drawdown, without prior Board approval. This facility provides for aggregate borrowings of less than 15 per cent. Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP, said "We are proud to partner with JPMorgan in the Company's inaugural credit facility. This new capital, together with expected cash flows from the portfolio, will provide greater flexibility in relation to new lending opportunities and provide complete coverage for downstream funding obligations."
rambutan2
24/4/2020
08:56
HTtp://bpcruk.com/2020/04/23/biopharma-credit-plc-investor-update-march-2020/
davebowler
30/3/2020
16:58
HTtp://bpcruk.com/2020/03/20/biopharma-credit-plc-investor-update-february-2020/
davebowler
10/3/2020
08:18
Annual report: https://www.investegate.co.uk/biopharma-credit-plc/bpcr/annual-financial-report/202003100700065194F/ "The balance of outstanding commitments at the end of 2019 is expected to be funded over the course of 2020." and "Follow-on commitments totalled $319 million as at 31 December 2019, of which most is expected to be funded during the second half of 2020." Then, "While the Company can raise equity and debt, it will also be important to monitor the potential early prepayment of loans in the portfolio in order to ensure the maximum amount of funds are deployed at all times."
jonwig
16/2/2020
20:02
Confirms that now more than fully invested: htTps://citywire.co.uk/investment-trust-insider/news/7-yielding-biopharma-deserves-some-credit-after-big-loan-to-us-opioid-provider/a1322536?re=72028&ea=134830&utm_source=BulkEmail_Investment+Trust+Insider+Weekend&utm_medium=BulkEmail_Investment+Trust+Insider+Weekend&utm_campaign=BulkEmail_Investment+Trust+Insider+Weekend
rambutan2
12/2/2020
13:51
WilliamC - NAV at 102c is higher than the share price. They won't try new equity until they can reverse that. I think ram was suggesting debt.
jonwig
12/2/2020
13:05
Hope it raises equity - should be able to do at around NAV - bigger = diversified = better - my concern has always been the borrower concentration risk Have been happy to hold a little position
williamcooper104
12/2/2020
09:52
By coincidence, a related company is planning IPO (BPCR is mentioned): https://www.ft.com/content/0797fd6c-4d68-11ea-95a0-43d18ec715f5 A Canadian healthcare investment group has chosen London to float its flagship fund, reinforcing the UK market’s status as a hub for alternative income investments. DRI Capital of Toronto operates funds that buy long-term royalty rights for pharmaceutical products from the inventors, research institutions and companies involved with their development. The group said today it was seeking to raise $350m by listing DRI Healthcare, a closed-ended investment company, on the London Stock Exchange’s premium segment. Behzad Khosrowshahi, chief executive of DRI Capital, said familiarity made London the best fit for the float. The LSE already hosts royalty collection vehicles including BioPharma Credit, a sector peer, and music rights manager Hipgnosis Songs Fund, all of which promise investors returns uncorrelated with conventional asset classes. “There’s an understanding of the business model,” Mr Khosrowshahi said. “It’s a totally vibrant sector in the LSE. An investor base exists in and around the UK who are frequent investors in the space, so that definitely gives us a bit of a running start.” DRI typically buys rights to established pharmaceuticals that pay out royalties for a decade or more, which Mr Khosrowshahi said was better suited to public markets than private capital. “Private equity funds tend to have shorter and shorter lives now, and putting a ten to 12 year long asset into a vehicle with a five to seven year long life just didn’t make sense for us,” he said. The company plans to use the float proceeds to buy assets from three of its existing funds for an aggregate cost of $458.8m. Annual royalties from this seed portfolio are expected to shrink from over $60m a year in 2020 to around $20m by 2027 so future value growth will depend on the acquisition pipeline. DRI’s independent board handles investment decisions while the listed vehicle will be chaired by Paul Mussenden, who was general counsel and head of strategic affairs at UK pharmaceuticals group BTG from 2000 until its takeover in 2019 by Boston Scientific. More than a quarter of DRI Healthcare’s initial gross asset value post float will be tied to income from Spinraza, a spinal muscular atrophy injection sold by Biogen. It is among the most expensive drugs in the world, with a US list price of $125,000 per dose, and could face competition later this year after US regulators fast-tracked for approval a rival oral treatment developed by Roche and PTC Therapeutics. Mr Khosrowshahi said DRI’s asset valuation models were reflecting competitive threats as well as factoring in long-term drug price deflation in all developed markets. “The nice thing about the pharmaceutical industry is that it typically takes between eight and 12 years for a drug to be developed and come to market. That process is very transparent,” he said. DRI was also prepared for any outcome in the 2020 US presidential election, he said. “We’re kind of indifferent to the methodology but we are modelling for US drug prices to be controlled in some fashion, regardless of whether Bernie Sanders makes it [to the White House] or not.”
jonwig
Chat Pages: 2  1
ADVFN Advertorial
Your Recent History
LSE
BPCR
Biopharma ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210227 05:15:52